22 citations
,
September 2020 in “Journal of the American Academy of Dermatology” Apremilast may be a promising long-term treatment for hidradenitis suppurativa.
20 citations
,
October 2024 in “British Journal of Dermatology” The guideline provides recommendations for managing alopecia areata effectively.
3 citations
,
July 2023 in “International journal of molecular sciences” Stress may contribute to hair loss in alopecia areata by affecting immune responses and cell death in hair follicles.
1 citations
,
December 2024 in “Indian Dermatology Online Journal” Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
1 citations
,
May 2013 in “Oncology Times” ODAC members faced intense pressure but prioritized scientific evidence in drug approval decisions.
4 citations
,
July 2023 in “Nature Medicine” The FDA approved a new Pfizer drug for hair loss in teens.
May 2022 in “Reactions Weekly”
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
16 citations
,
September 1990 in “Fertility and sterility” Ketoconazole can treat ovarian hyperandrogenism but should be used cautiously with monitoring and birth control.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
20 citations
,
August 2023 in “Saudi Pharmaceutical Journal” Niosomes can effectively deliver cetirizine topically for treating alopecia.
24 citations
,
July 1983 in “Clinical and Experimental Dermatology” Tigason improved hair growth in a boy with monilethrix without side effects.
3 citations
,
October 2018 in “Journal of cosmetic dermatology” Pentoxifylline alone and combined with triamcinolone acetonide is effective for treating localized alopecia areata, with the combination showing the highest effectiveness.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
March 2023 in “PARIPEX INDIAN JOURNAL OF RESEARCH” Tofacitinib helped regrow hair in most patients with severe hair loss.
1 citations
,
January 2009 in “Actas Dermo-Sifiliográficas” Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.